STL Index for: Secukinumab
Drug update covering: Adalimumab-adbm for SC use - Cyltezo®, Tralokinumab for SC use - Adtralza® (in Canada), Tralokinumab-ldrm for SC use - Adbry™ (in US), Melanoma vaccine for IV use - BNT111, Adalimumab-aqvh for SC use - Yusimry™, and more...
Although biologics are well-studied, expertise regarding their use is often lacking. Many biologics have been added to the market in recent years with distinctive characteristics. This study was designed to create a tool to assist physicians involved in the care of patients with psoriasis undergoing biologic treatment.
The update covers: Secukinumab for SC use - Cosentyx® (Novartis), Brincidofovir tablets and oral suspension - Tembexa® (Chimerix), Plasminogen, humantvmh - Ryplazim® (Liminal BioSciences), Halobetasol propionate lotion 0.01% w/w - Bryhali™ (Bausch Health), and Nomacopan for SC use (Akari Therapeutics).
Update on Drugs & Devices May and June 2018: Tildrakizumab-asmn for SC injection Ilumya™, Lidocaine topical system 1.8% for postherpetic neuralgia ZTlido™, Secukinumab for SC injection Cosentyx®, Vaginal gel for prevention of urogenital chlamydia Amphora®.
Interleukin (IL)-17 is important in the pathophysiology of psoriasis and has proven to be an effective therapeutic target. As brodalumab enters the marketplace, a review of this important biologic, its safety profile, and discussion of possible adverse effects is in order.
September-October 2017 Update on drugs include Isopropyl myristate solution Resultz®, Delafloxacin oral and IV formulations Baxdela™, Plasma-derived concentrate of C1 esterase inhibitor SC (human) Haegarda®, Oral dimethyl fumarate Skilarence®, Abatacept for IV or SC injection Orencia®, Consentyx®, Tremfya™, Yervoy® and Benlysta®.
Secukinumab demonstrates rapid and robust clinical improvement accompanied by a favorable short- term safety profile. The results of the phase III trials continue to reinforce the theory that the IL-17 pathway is an essential target in psoriasis and psoriatic arthritis treatment.
Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia. Interleukin (IL)-17 signaling has a central role in its pathogenesis, and is being looked at as a target. The rationale for IL-17 inhibitors, clinical trial results of new drugs like Brodalumab are included.
In this review, we summarize the most common immunosuppressant medications currently used in dermatology, and provide recommendations for infection screening prior to initiating treatment.
A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis
Recent advances in our understanding of the innate and adaptive immune systems have led to the identification of interleukin (IL)-17 as a key pro-inflammatory mediator in psoriasis. We review phase 1-3 clinical trials of ixekizumab, for treatment of moderate-to-severe plaque psoriasis.
Update on (Beteflam™), Human papillomavirus (HPV) 9-valent vaccine, recombinant (Gardasil®9), (Imlygic®), Pembrolizumab IV injection (Keytruda®), Adalimumab SC injection (Humira®), Secukinumab SC injection (Cosentyx®), Ustekinumab SC injection (Stelara®), and Nivolumab + ipilimumab (Opdivo® + Yervoy®).
An overview and update of skin treatments introduced in 2015: Quick overview of drug name, indications and regulatory status. Deoxycholic acid injection, 5-fluorouracil 0.5% + salicylic acid 10% solution, Adapalene 0.3% + benzoyl peroxide 2.5% gel, and more are covered.
Update on Human papillomavirus 9-valent vaccine, recombinant (Gardasil®9), Ivermectin 1% cream (Soolantra®), Naftifine HCl 2% gel & cream (Naftin®), Nivolumab IV infusion (Opdivo®), Polymethylmethacrylate collagen dermal filler for acne scars (Bellafill®), Secukinumab SC injection (Consentyx™).
Interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. This article reviews efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) for the treatment of plaque psoriasis.